Media: EU will not renew contracts with two vaccine manufacturers



[ad_1]

“The EC, in consultation with the leaders of many EU countries, has decided that contracts with companies that produce vaccines (viral vectors) this year will not be renewed next year,” the newspaper said.

It is also announced that Brussels will focus on COVID-19 vaccines based on mRNA technology, such as Pfizer and Moderna.

The EC is awaiting clarification from J&J on the company’s “completely unexpected” announcement of the suspension of COVID-19 vaccines in the EU, an EU official told Reuters on Tuesday.

Johnson & Johnson announced Tuesday that it was delaying the distribution of the COVID-19 vaccine in Europe after US drug regulatory authorities suspended vaccination with the vaccine for safety reasons.

The US Food and Drug Administration and the Centers for Disease Control have decided to temporarily suspend vaccination with this vaccine following reports of six rare blood clots in vaccinated patients in the United States.

“We have decided to postpone the distribution of our vaccine in Europe,” Johnson & Johnson reported. The report also adds that the company is reviewing these cases with European health officials.

“We work closely with medical experts and healthcare officials and strongly advocate for open access to this information for healthcare professionals and the public,” said Johnson & Johnson.

US health officials have recommended stopping the vaccine, “taking extra precautions,” until the link between the vaccine and rare blood clots is investigated.

All cases were reported in women aged 18 to 48 years, 6 to 13 days after vaccination.

Similar clots have been reported after vaccination with AstraZeneca in Europe. Both vaccines have been developed using similar adenovirus vector technology.

Johnson & Johnson’s suspension of vaccination is a major blow to one of the fastest coronavirus vaccination campaigns in the world, with 45% receiving a single dose of vaccine. adult population of the country.

Additionally, the vaccine is valued because it is sufficient for a single dose and because it does not need to be stored at extremely low temperatures, unlike Moderna and Pfizer-BioNTech vaccines, which greatly facilitate the distribution of Johnson & Johnson vaccines.

It is strictly forbidden to use the information published by DELFI on other websites, in the media or elsewhere, or to distribute our material in any way without consent, and if consent has been obtained, it is necessary to indicate DELFI as the source .



[ad_2]